Zhitong Finance App News, Shiyao Group (01093.HK) announced that the Phase III clinical trial (HB1801-017) of injectable docetaxel (albumin binding) (HB1801) developed by the Group for the treatment of advanced breast cancer () has recently been officially launched at the first research center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.